December 7, 2011

Sanofi reports results of new meta-analysis reinforcing Lantus® safety profile at the World Diabetes Congress

- Analysis of all published studies further expand the evidence base on the safety of Lantus® (insulin glargine) -

 

Sanofi reports results of new meta-analysis reinforcing Lantus® safety profile at the World Diabetes Congress
- Analysis of all published studies further expand the evidence base on the safety of Lantus® (insulin glargine) -

Paris, France – December 7, 2011 – Sanofi (EURONEXT: SAN and NYSE: SNY) announced today the presentation of new meta-analysis data at the World Diabetes Congress in Dubai, adding to the wealth of evidence resulting from more than 80,000 patients enrolled in clinical trials and 38 million patient years of treatment exposure to Lantus® (insulin glargine). This new meta-analysis on the relationship between diabetes and cancer risk demonstrates no increased risk in people using Lantus® (insulin glargine).1